Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.

Journal of medicinal chemistry - 27 Sept 2018

Cho Hanna, Shin Injae, Ju Eunhye, Choi Seunghye, Hur Wooyoung, Kim Haelee, Hong Eunmi, Kim Nam Doo, Choi Hwan Geun, Gray Nathanael S, Sim Taebo

Abstract excerpt

GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, 10d, 10g, and 11i, which possess single-digit nanomolar inhibitory activity against both ACK1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mice, Nude

Share to Molecular Structure

Share to Protein Kinase Inhibitors

Share to Structure-Activity Relationship

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 30153003
DOI: 10.1021/acs.jmedchem.8b00882

Genes

NRAS
GCK

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.PMID 30153003Read ↗

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.Semantic proximity Read ↗

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemiaSemantic proximity Read ↗

Discovery of a Novel MNK Inhibitor (NSP-1047) with In Vivo Anti-acute Myeloid Leukemia ActivitySemantic proximity Read ↗

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.Semantic proximity Read ↗

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.Semantic proximity Read ↗

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.Semantic proximity Read ↗

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Semantic proximity Read ↗

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanismsSemantic proximity Read ↗

The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.Semantic proximity Read ↗

Discovery of 2-Aminopyrimidine Derivatives as Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced hERG Inhibitory Activities.Semantic proximity Read ↗

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.Semantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.